Predict your next investment

HEALTHCARE | Drug Discovery

See what CB Insights has to offer

Business Relationships

2

RuiYi Partners & Customers

2 Partners and customers

RuiYi has 2 strategic partners and customers. RuiYi recently partnered with arGEN-X on October 10, 2012.

Date

Type

Business Partner

Country

News Snippet

Sources

10/4/2012

Licensor

arGEN-X

Netherlands

arGEN X : rsquo; Partner RuiYi, Inc. Announces First Human... read more... (Sep 23 2015)

Breda , the Netherlands / Ghent , Belgium - arGEN-X N.V. , a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases , today reports that its partner RuiYi , Inc. , a company focused on the discovery and development of novel biologic therapies , has announced the first human dosing of Gerilimzumab , a novel monoclonal antibody neutralizing the IL-6 cytokine , for the treatment of autoimmune disorders including rheumatoid arthritis .

5

10/4/2012

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/4/2012

10/4/2012

Type

Licensor

Licensor

Business Partner

arGEN-X

Country

Netherlands

Subscribe to see more

News Snippet

arGEN X : rsquo; Partner RuiYi, Inc. Announces First Human... read more... (Sep 23 2015)

Breda , the Netherlands / Ghent , Belgium - arGEN-X N.V. , a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases , today reports that its partner RuiYi , Inc. , a company focused on the discovery and development of novel biologic therapies , has announced the first human dosing of Gerilimzumab , a novel monoclonal antibody neutralizing the IL-6 cytokine , for the treatment of autoimmune disorders including rheumatoid arthritis .

Subscribe to see more

Subscribe to see more

Sources

5

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.